

II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

A. Listing of Claims

Claim 1. (Original) A method for managing a patient with Alzheimer's disease or at risk of developing Alzheimer's disease comprising:
providing to said patient a therapeutic agent which lowers A β levels, and
detecting a level of A β in a body fluid of said patient to determine the efficacy of said therapeutic agent.

Claim 2. (Original) The method of claim 1 wherein said therapeutic agent is an HMG CoA reductase inhibitor, an NSAID, secretase modifier or a combination thereof.

Claim 3. (Original) The method of claim 1, further comprising repeatedly detecting the level of A β in a body fluid.

Claim 4. (Original) The method of claim 1, further comprising repeatedly providing said therapeutic agent according to a dosing interval.

Claim 5. (Original) The method of claim 4, further comprising repeatedly detecting the level of A β in a body fluid.

Claim 6. (Original) The method of claim 5, further comprising a detected the level of A β in said body fluid with at least one previously detected level of A β .

Claim 7. (Original) The method of claim 6, further comprising adjusting the repeated dosing of said therapeutic agent based on said comparison.

Claim 8. (Original) The method of claim 1, wherein said body fluid is blood plasma or serum.

Claim 9. (Original) The method of claim 1, wherein said therapeutic agent is an HMG-CoA reductase inhibitor.

Claim 10. (Original) The method of claim 9, wherein said HMG-CoA reductase is selected from the group consisting of mevastatin, pravastatin, simvastatin, atorvastatin, lovastatin, rivastatin, fluvastatin, pharmaceutically acceptable salts thereof, isomers thereof, and active metabolite thereof.

Claim 11. (Original) The method of claim 9, wherein said HMG-CoA reductase inhibitor is lovastatin or a pharmaceutically acceptable salt thereof.

Claim 12. (Original) The method of claim 9, wherein said HMG-CoA reductase inhibitor is in a controlled release oral dosage form.

Claim 13. (Original) The method of claim 1, wherein said levels of A β are detected in said body fluid using an assay.

Claim 14. (Original) The method of claim 1, wherein said assay selected from the group consisting of radioimmunoassay, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, western blots, protein A immunoassays, and immunoelectro-phoresis assays, and combination thereof.

300.1042

Claim 15. (Original) The method of claim 13, wherein said assay is an ELISA.

Claim 16. (Original) The method of claim 1, further comprising detecting a baseline level of A β prior to providing said therapeutic agent.

Claim 17-40 (Cancelled)